BioVersys and Shionogi Enter Into Global Research Collaboration For Broad-Spectrum Non-Tuberculous Mycobacteria (NTM) Clinical Candidate
July 02, 2025 01:00 ET Â | Source: BioVersys Ad hoc announcement pursuant…
OSE Immunotherapeutics met jour linformation sur les procdures en cours
OSE Immunotherapeutics provides an update on ongoing proceedings NANTES, France, July 2,…
Addex Therapeutics Reports Q1 2025 Financial Results and Provides Corporate Update
June 19, 2025 01:00 ET Â | Source: Addex Therapeutics Strong cash position…
FOBI AI Inc. Announces Closing of the Sale of German Subsidiary
June 12, 2025 16:53 ET Â | Source: Fobi AI Inc. Vancouver, BC,…
Novartis Pluvicto demonstrates statistically significant and clinically meaningful rPFS benefit in patients with PSMA-positive metastatic hormone-sensitive prostate cancer
Ad hoc announcement pursuant to Art. 53 LR At interim analysis, PSMAddition…
![Sandoz launches first and only interchangeable denosumab biosimilars in US, providing new affordable treatment options for over 10 million patients[1]](https://i0.wp.com/ml-eu.globenewswire.com/media/NjEzMmQ4NzAtZTBkMS00ZDhhLTkyYjgtOGM3YzY1ZWM5M2U5LTEwMTQyODItMjAyNS0wNi0wMi1lbg==/tiny/Sandoz-International-GmbH.png?w=420&resize=420,280&ssl=1 "Sandoz launches first and only interchangeable denosumab biosimilars in US, providing new affordable treatment options for over 10 million patients[1]")
Sandoz launches first and only interchangeable denosumab biosimilars in US, providing new affordable treatment options for over 10 million patients[1]
Ad-hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules MEDIA…